October 23, 2024 11:26 AM EDT
News Briefing

Ec­co­gene gets $60M from As­traZeneca; Evotec al­so records mile­stone with BMS

ENDPOINTS

Plus, news about DBV, Dou­ble Point Ven­tures and Lu­mos:

Ec­co­gene’s $60M mile­stone from As­traZeneca: The pay­ment ar­rived af­ter Ec­co­gene met sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times